WallStSmart
RNTX

Rein Therapeutics Inc

NASDAQ: RNTX · HEALTHCARE · BIOTECHNOLOGY

$1.15
+0.00% today

Updated 2026-06-04

Market cap
$78.73M
P/E ratio
P/S ratio
EPS (TTM)
$-1.90
Dividend yield
52W range
$1 – $2
Volume
0.7M

Rein Therapeutics Inc (RNTX) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item202020212022202320242025
Revenue$0.00$0.00$0.00$0.00$0.00$0.00
Revenue growth (YoY)
Cost of revenue$63000.00$1000.00
Gross profit$-63000.00$-1000.00
Gross margin
R&D$11166.00$17008.00$17967.00$3991.00$14.25M$11.03M
SG&A$9330.00$9597.00$9680.00$11357.00$13.86M$10.90M
Operating income$-20496.00$-26605.00$-27647.00$-16276.00$-65.11M$-21.93M
Operating margin
EBITDA$-20333.00$-26484.00$-27478.00$-15229.00$-28.05M$-21.93M
EBITDA margin
EBIT$-20496.00$-26605.00$-27647.00$-15348.00$-28.11M$-21.93M
Interest expense
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-21157.00$-26164.00$-27329.00$-15732.00$-62.88M$-49.87M
Net income growth (YoY)-23.7%-4.5%+42.4%-399614.0%+20.7%
Profit margin

Frequently asked questions

How much free cash flow does RNTX generate?

RNTX produced $-19.36M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is RNTX's balance sheet healthy?

RNTX holds $3.21M in cash and equivalents against — in long-term debt, on $16.92M of shareholder equity. That debt is best read against the cash flow the business throws off each year.